Adamis Pharmaceuticals Corp
Company Snapshot: Adamis Pharmaceuticals Corp
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology. In its specialty pharmaceutical pipeline, ADMP is developing low cost therapeutic alternatives for the treatment of anaphylaxis, asthma, chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Within the Company's biotechnology pipeline is a novel cell-based therapeutic cancer vaccine and three drug candidates for the treatment of prostate cancer.
- May 18 2022 Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
- May 16 2022 Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
- May 9 2022 Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
- Mar 31 2022 Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update